GCCA
14.3.2023 14:02:00 CET | Business Wire | Press release
Start-ups from around the world can play a leading role in helping an essential global industry in its efforts to cut CO2 emissions and help solve the climate challenge. They are being invited to apply for the Innovandi Open Challenge, an exciting international partnership programme, run by the Global Cement and Concrete Association (GCCA) and its member companies across the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005357/en/
Applications for the 2023 GCCA Innovandi Open Challenge are now open (Graphic: Business Wire)
Applicants are being asked to work on the development of new materials and ingredients for low carbon concrete – a major step towards the ultimate goal of net zero concrete.
Innovation can help further unlock the delivery of low carbon concrete by reducing the amount of clinker used - the carbon intensive element of cement - or by using the most cutting-edge manufacturing processes. Alternative materials, including construction and demolition waste, can result in much lower CO2 emissions than concrete made in the traditional method, as well as reduce the need to use virgin raw materials.
The global challenge matches start-up companies with some of the world’s leading cement and concrete manufacturers, who operate in almost every country across the world, to work on initiatives to cut emissions and pioneer environmental change across the industry.
The GCCA and its members account for 80% of global cement production capacity outside of China, as well as some key Chinese manufacturers. Member companies have committed to reducing and ultimately eliminating CO2 emissions in concrete (which currently account for around 7% globally), through implementation of the GCCA’s Concrete Future 2050 Net Zero Roadmap – the first heavy industry to set out such a detailed plan.
The launch follows the success of last year’s first ever Innovandi Open Challenge, which saw cement companies partnering with six start-ups, with a strong focus on carbon capture and utilisation projects. Three of those projects have already gone to pilot stage.
Thomas Guillot, Chief Executive of the GCCA, said:
“We’re calling on the best and the brightest from around the world to join us in the urgent fight to limit global warming and help towards delivering the great prize of net zero concrete. If you are a start up from Austria to Australia, from Brazil to Bangladesh, with an innovative idea or technology, then we want to hear from you.”
“Concrete is the second most used substance on earth after water and is a vital part of our modern infrastructure. The GCCA and all our members are working hard to reduce emissions. And start-ups can play a big role in helping us to do that.”
Start-ups can find more information and apply to take part in the Innovandi Open Challenge by going to the GCCA Open Challenge webpage:
https://gccassociation.org/innovandi/openchallenge/oc2023
Those companies who are accepted for this year’s Innovandi Open Challenge, will gain unique access to industry plants, labs, key networks and the expertise and infrastructure of the GCCA’s 40 members from around the world. They will also receive guidance from the GCCA and its members to help them with the development of new technology and business cases.
Claude Loréa, GCCA Cement Director and Innovation Lead said:
“We’ve already seen some remarkable progress from those start-ups who’ve been working with our members on the first Innovandi Open Challenge, with several projects already in the pilot stage. This year’s theme, low carbon concrete, is equally challenging. To succeed, we need products which are affordable, scalable, and easily adopted. Good luck to all this year’s applicants. We look forward to working with those selected.”
Natalie Giglio is Senior Business Development Associate, at Carbon Upcycling Technologies in Canada, which took part in the first Innovandi Open Challenge. She encourages all start-ups interested in working on net-zero initiatives to apply:
"The Innovandi program is specifically designed to foster collaboration among the largest global cement producers, and start-ups, which is an opportunity unique to this challenge. Our initiative focused on validating materials at the lab scale, and now the results have set a foundation for further collaboration and project development.”
/ Ends
Notes to editors:
The Innovandi Open Challenge is open to applicants from 14th March 2023, with applications closing on 30th May 2023.
For more information click here:
Additional quotes from start-ups which have taken part in the 1st Innovandi Open Challenge:
Carbon BioCapture is based in the USA and has patented technology for CO2 capture using microalgae (microscopic algae invisible to the naked eye.) CEO Andrea Irarrazaval said: “It has been a great opportunity and an honour for Carbon BioCapture (CBC) to be selected in GCCA's Open Challenge global programme… Participation provides valuable means for tech start-ups to access, obtain growth assistance, and help to demonstrate their technology potential to the critical cement and concrete global industry."
CarbonOrO, based in the Netherlands, specializes in carbon capture technology using unique bi-phasic amine. Spokesperson Jan Hoppenbrouwers said: “There is a lot of talk about carbon capture, utilisation and storage but worldwide, we need to accelerate the number of pilots and move towards commercial scale roll-out. GCCA members and their consortia’s joined efforts have all the characteristics to change this. So, our advice, participate in this challenge.”
Coomtech based in the UK, has developed a low energy, low cost drying technology using managed turbulent air, creating kinetic energy to remove moisture. Founder Chris Every said: “Coomtech took part in the Innovandi Open Challenge to showcase its technology at a global level to the cement and concrete industry. Innovandi has been highly supportive and is commercially attuned to new technologies. The connections the program makes are an excellent springboard for emerging technology businesses focused on the vital cement and concrete sector.”
Fortera, based in the USA, uses technology to capture CO2 emissions from cement plants, combining it with calcium oxide to make reactive calcium carbonate. Vice President Kas Farsad, said: “The Innovandi Open Challenge platform allowed Fortera to engage multiple cement players simultaneously and really dig into not just industry pain points, but brainstorm on solutions with the broader industry in mind. Whether you're looking to launch a pilot plant or to validate a commercial offering, you'll get a committed consortium of GCCA members supporting your process."
MOF Technologies, based in the UK, is using modern sorbents called metal-organic frameworks (MOFs) to engineer a filtration system to capture and remove CO2 from flue gas. Conor Hamill, Co-CEO said: “Having developed a carbon capture system that overcomes the traditional adoption barriers of energy and cost, we are thrilled to have had the opportunity to collaborate with GCCA members to bring our technology to the field. We are currently working with an innovative consortium to pilot our ultra-efficient Nuada technology which will validate its potential to provide the industry with a scalable low-cost carbon capture solution.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005357/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
